Active Ingredient History
Guanfacine (marketed under the brand names Estulic, Tenex and the extended release Intuniv) is a sympatholytic drug, indicated for the management of hypertension. Tenex (guanfacine hydrochloride) is an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α2-adrenergic receptors. By stimulating these receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. Guanfacine is also used in the treatment of attention deficit hyperactivity disorder. Intuniv is an extended-release version of guanfacine that is used to treat symptoms of ADHD. It can be used by itself or with stimulant medications also used to treat symptoms of ADHD. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertension (approved 1986)
Abnormalities, Multiple (Phase 4)
Aggression (Phase 4)
Alcohol Abstinence (Phase 1/Phase 2)
Alcohol Drinking (Phase 2)
Alcohol-Induced Disorders (Phase 2)
Alzheimer Disease (Phase 3)
Antihypertensive Agents (Phase 4)
Anxiety Disorders (Phase 2)
Anxiety, Separation (Phase 2)
Behavioral Symptoms (Phase 4)
Cannabis (Phase 2)
Child Development Disorders, Pervasive (Phase 4)
Chromosome Disorders (Phase 4)
Chronic Pain (Phase 4)
Cocaine-Related Disorders (Phase 2)
Cognitive Dysfunction (Phase 4)
Congenital Abnormalities (Phase 4)
Critical Illness (Phase 2)
Delirium (Phase 3)
Depressive Disorder, Major (Phase 4)
Dermatology (Phase 4)
Genetic Diseases, Inborn (Phase 4)
Healthy Volunteers (Phase 1)
Hypertension ()
Intellectual Disability (Phase 4)
Marijuana Abuse (Phase 1)
Nervous System Diseases (Phase 4)
Neurobehavioral Manifestations (Phase 4)
Neurologic Manifestations (Phase 4)
Neurotransmitter Agents (Phase 4)
Nutrition Disorders (Phase 4)
Obesity (Phase 4)
Overnutrition (Phase 4)
Pathologic Processes (Phase 4)
Pediatrics (Phase 4)
Perceptual Disorders (Phase 2)
Personality Disorders (Phase 4)
Phobia, Social (Phase 2)
Physiological Effects of Drugs (Phase 4)
Prader-Willi Syndrome (Phase 4)
Psychological Distress (Phase 4)
Psychotic Disorders (Phase 4)
Reading (Phase 4)
Schizophrenia (Phase 4)
Schizotypal Personality Disorder (Phase 4)
Self-Injurious Behavior (Phase 4)
Sensory Thresholds (Phase 2)
Sleep Apnea, Obstructive (Phase 4)
Sleep Wake Disorders (Phase 4)
Smoking (Phase 2)
Smoking Cessation (Phase 2)
Stress Disorders, Post-Traumatic (Phase 1)
Stroke (Phase 2)
Substance-Related Disorders (Phase 2)
Tourette Syndrome (Phase 4)
Trigeminal Neuralgia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
